MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution
Journal of Clinical Investigation · 15.05.2024 · 134 (10)
DOI: 10.1172/jci172826 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 21.03.2024. Verfasst von Sean M Fortier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Dual Specificity Phosphatase 1, Myofibroblasts, Mitogen-Activated Protein Kinase 14, Pulmonary Fibrosis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAMS NIH HHS, NHLBI.
Abstract (Originalsprache)
Fibrosis following tissue injury is distinguished from normal repair by the accumulation of pathogenic and apoptosis-resistant myofibroblasts (MFs), which arise primarily by differentiation from resident fibroblasts. Endogenous molecular brakes that promote MF dedifferentiation and clearance during spontaneous resolution of experimental lung fibrosis may provide insights that could inform and improve the treatment of progressive pulmonary fibrosis in patients. MAPK phosphatase 1 (MKP1) influences the cellular phenotype and fate through precise and timely regulation of MAPK activity within various cell types and tissues, yet its role in lung fibroblasts and pulmonary fibrosis has not been explored. Using gain- and loss-of-function studies, we found that MKP1 promoted lung MF dedifferentiation and restored the sensitivity of these cells to apoptosis — effects determined to be mainly dependent on MKP1’s dephosphorylation of p38α MAPK (p38α). Fibroblast-specific deletion of MKP1 following peak bleomycin-induced lung fibrosis largely abrogated its subsequent spontaneous resolution. Such resolution was restored by treating these transgenic mice with the p38α inhibitor VX-702. We conclude that MKP1 is a critical antifibrotic brake whose inhibition of pathogenic p38α in lung fibroblasts is necessary for fibrosis resolution following lung injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA.
Förderung
- NHLBI NIH HHS
- NIAMS NIH HHS
- NHLBI
- NIAMS
Zitieren
APA
Fortier, S. M., Walker, N. M., Penke, L. R., Baas, J. D., Shen, Q., Speth, J. M., Huang, S. K., Zemans, R. L., Bennett, A. M., & Peters-Golden, M. (2024). MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution. Journal of Clinical Investigation, 134(10). https://doi.org/10.1172/jci172826
Vancouver
Fortier SM, Walker NM, Penke LR, Baas JD, Shen Q, Speth JM, et al. MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution. Journal of Clinical Investigation. 2024;134(10). doi:10.1172/jci172826
BibTeX
@article{Fortier2024,
author = {Fortier, Sean M and Walker, Natalie M and Penke, Loka R and Baas, Jared D and Shen, Qinxue and Speth, Jennifer M and Huang, Steven K and Zemans, Rachel L and Bennett, Anton M and Peters-Golden, Marc},
title = {MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {10},
doi = {10.1172/jci172826}
}
EUVIMED